These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12903649)

  • 1. HDL Cholesterol: Metabolic Pathways and Drug Developments. 4th International Conference, March 2-4, 2003, Cambridge, MA, USA.
    Scriabine A
    Cardiovasc Drug Rev; 2003; 21(2):143-50. PubMed ID: 12903649
    [No Abstract]   [Full Text] [Related]  

  • 2. HDL cholesterol: metabolic pathways and drug developments. Fifth Annual International Conference of the Knowledge Foundation. March 8-9, 2004, Cambridge, MA, USA.
    Scriabine A
    Cardiovasc Drug Rev; 2004; 22(2):147-53. PubMed ID: 15499703
    [No Abstract]   [Full Text] [Related]  

  • 3. HDL Cholesterol 2003--Fourth Annual International Conference. Metabolic pathways and drug targets. 2-4 March 2003, Cambridge, MA, USA.
    Meng CQ
    IDrugs; 2003 Apr; 6(4):294-6. PubMed ID: 12838990
    [No Abstract]   [Full Text] [Related]  

  • 4. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?
    Rader DJ; Tall AR
    Nat Med; 2012 Sep; 18(9):1344-6. PubMed ID: 22961164
    [No Abstract]   [Full Text] [Related]  

  • 5. Intervening on HDL-C: is it possible? Does it work?
    Wierzbicki AS
    Int J Clin Pract; 2007 Nov; 61(11):1782-6. PubMed ID: 17935541
    [No Abstract]   [Full Text] [Related]  

  • 6. Raising HDL-C: back to the future?
    Wierzbicki AS
    Int J Clin Pract; 2007 Jul; 61(7):1069-71. PubMed ID: 17577290
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipoproteins and coronary heart disease.
    Krauss RM
    Postgrad Med; 1989 Apr; Spec No():54-8; discussion 89-90. PubMed ID: 2726627
    [No Abstract]   [Full Text] [Related]  

  • 8. 5th Annual International Conference on HDL Cholesterol: metabolic pathways and drug developments.
    Davidson WS
    Expert Opin Ther Targets; 2004 Aug; 8(4):359-66. PubMed ID: 15268630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.
    Sirtori CR; Franceschini G
    N Engl J Med; 1997 Dec; 337(26):1918; author reply 1919. PubMed ID: 9417525
    [No Abstract]   [Full Text] [Related]  

  • 10. [HDL: the yin-yang of cardiovascular disease].
    Leança CC; Passarelli M; Nakandakare ER; Quintão EC
    Arq Bras Endocrinol Metabol; 2010 Dec; 54(9):777-84. PubMed ID: 21340169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 12. HDL therapy for the treatment of cardiovascular diseases.
    Parolini C; Marchesi M; Chiesa G
    Curr Vasc Pharmacol; 2009 Oct; 7(4):550-6. PubMed ID: 19485919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High HDL may not protect the heart. Concentrate on lowering LDL for now, experts advise.
    Harv Heart Lett; 2012 Sep; 23(1):6. PubMed ID: 23097807
    [No Abstract]   [Full Text] [Related]  

  • 14. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.
    Noto H; Kawamura M; Hashimoto Y; Satoh H; Hara M; Iso-o N; Togo M; Kimura S; Tsukamoto K
    Atherosclerosis; 2003 Nov; 171(1):131-6. PubMed ID: 14642415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the editor: selling the benefit of drug therapy.
    Brown WV
    J Clin Lipidol; 2013; 7(1):1-2. PubMed ID: 23351576
    [No Abstract]   [Full Text] [Related]  

  • 16. HDL-cholesterol levels and cardiovascular risk: acCETPing the context.
    Lange RA; Lindsey ML
    Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471
    [No Abstract]   [Full Text] [Related]  

  • 17. From the editor: what are the important questions for clinical trials?
    Brown WV
    J Clin Lipidol; 2012; 6(4):299-300. PubMed ID: 22836064
    [No Abstract]   [Full Text] [Related]  

  • 18. What's new in cardiovascular prevention?
    Brohet CR
    Acta Clin Belg; 2007; 62(5):317-22. PubMed ID: 18229465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL and heart attack.
    Harv Heart Lett; 2012 Nov; 23(3):8. PubMed ID: 23409309
    [No Abstract]   [Full Text] [Related]  

  • 20. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.